Britain's medicines regulator has approved the oral version of the weight-loss drug Wegovy, a once-daily pill that can help patients with obesity lose up to 17 per cent of their body weight after 64 weeks. According to the report, the pill will initially be available only through private pharmacies including Boots, Superdrug, and Morrisons, with delivery expected by early July.. Discussions with the NHS over public coverage are understood to be underway, but no timetable has been set.

17% weight loss over 64 weeks – what the clinical trial showed

The Wegovy Pill contains the same active ingredient, semaglutide, as the injectable version, which already has a large user base in the UK . The source article notes that the oral formulation mimics a gut hormone that suppresses appetite, making patients feel fuller for longer. Clinical trial data reported in the source indicates that at the highest dose of 25 mg, participants achieved an average weight reduction of 17 per cent over roughly 64 weeks. The starting dose is 1.5 mg, escalating monthly to 4 mg, 9 mg, and finally 25 mg, with the tablet taken on an empty stomach with water.

Private pharmacies from Boots to Morrisons begin dispensing the pill

The approval immediately opens the drug to private buyers at prices expected to be lower than the injectable Wegovy. The source names high-street chains Morrisons, Superdrug, and Boots among the first pharmacies to stock the pill, alongside other licensed retailers. Industry observers expect the oral form to dramatically expand access because it removes the stigma and inconvenience of injections. The report says private waiting lists have already soared close to 100,000, a figure that underscores pent-up demand.

Why the 100,000-person waiting list signlas a demand surge

Beyond the immediate queue, the source estimates that at least 1.6 million British adults currently use weight-loss jabs, and a further 3.3 million are considering them. The arrival of an oral tablet could convert many of the 3.3 million into active patients, potentially straining supply and pricing.. The report does not name the specific private providers managing those waiting lists, leaving open questions about how quickly they can scale up and whether pricing will remain below injection costs as demand spikes.

NHS talks: no timetable for public access yet

While private sales begin immediately, the most critical unanswered question is when – or if – the Wegovy Pill will become available on the NHS. The source states that "discussions about making the treatment available on the NHS are understood to be taking place soon," but offers no specifics on cost-effectiveness reviews, budget impact, or a potential rollout date. Without NHS coverage, the pill will remain out of reach for the millions of British patients who cannot afford private treatment, widening the existing equity gap in obesity care.